Showing 21 - 40 results of 2,913 for search '"The Real World"', query time: 0.09s Refine Results
  1. 21

    Foot orientation and trajectory variability in locomotion: Effects of real-world terrain. by Emma Gibson, Greg Douglas, Katelyn Jeffries, Julianne Delaurier, Taylor Chestnut, Jesse M Charlton

    Published 2024-01-01
    “…This may be an important factor to consider when making comparisons of real-world walking bouts, as greater proportions of one terrain feature in a data set could create bias in the outcomes. …”
    Get full text
    Article
  2. 22

    Real world pharmacovigilance assessment of drug related macular degeneration risks by Xiaodong Chen, Shinan Wu, Shaopan Wang, Chaofeng Yu, Zihan Guo, Shiya Huang, Peixin Cai, Yanliang Miao, Shiying Li, Qian Chen

    Published 2025-01-01
    “…To enhance clinical practice and reduce the risk of drug-related macular degeneration, we analyzed drug-related trends using real-world data. Disproportionality analysis of adverse event reports from the FDA Adverse Event Reporting System (FAERS, 2004–2023) identified 67,683 cases involving 1402 drugs. …”
    Get full text
    Article
  3. 23

    Review of Challenges in Performing Real-World Evidence Studies for Nonprescription Products by Maihöfner C, Mallick-Searle T, Vollert J, Kalita P, Sood Sethi V

    Published 2025-01-01
    “…Ltd, SingaporeCorrespondence: Vidhu Sood Sethi, GSK Consumer Healthcare Singapore Pte Ltd (Co Regn No. 201309040M), 23 Rochester Park #03-02, 139234, Singapore, Tel +6596447203, Email vidhu.x.sethi@haleon.comAbstract: In recent years, regulatory authorities have signaled a willingness to consider real-world evidence (RWE) data to support applications for new claims and indications for pharmaceuticals. …”
    Get full text
    Article
  4. 24

    Real-world experience with TTFields in glioma patients with emphasis on therapy usage by Claudius Jelgersma, Joan Alsolivany, Gülsüm Akkas, David Wasilewski, David Wasilewski, Bastian Gastl, Martin Misch, David Capper, David Capper, David Kaul, David Kaul, Lars Bullinger, Lars Bullinger, Peter Vajkoczy, Julia Onken, Julia Onken, Julia Onken

    Published 2025-01-01
    “…Given the cost-intensive nature and mild- to- moderate constraints associated with the therapy, our objective is to generate real-world data on therapy usage through a retrospective analysis at a high-throughput academic center. …”
    Get full text
    Article
  5. 25
  6. 26

    Differences in Energy Consumption in Electric Vehicles: An Exploratory Real-World Study in Beijing by Kezhen Hu, Jianping Wu, Tim Schwanen

    Published 2017-01-01
    “…This paper explores how the energy efficiency of EVs is affected and shaped by driving behavior, personal driving styles, traffic conditions, and infrastructure design in the real world. Tests have been conducted with a Nissan LEAF under a typical driving cycle on the Beijing road network in order to improve understanding of variations in energy efficiency among drivers under different urban traffic conditions. …”
    Get full text
    Article
  7. 27
  8. 28

    Real-world evaluation of an evidence-based telemental health program for PTSD symptoms by Jocelynn T. Owusu, Lu Wang, Shih-Yin Chen, Robert E. Wickham, Scott T. Michael, Nazneen F. Bahrassa, Alethea Varra, Jennifer L. Lee, Connie Chen, Anita Lungu

    Published 2025-01-01
    “…However, its effectiveness in diverse, real-world settings is not well-understood. This evaluation aimed to assess clinical outcomes of a BCT program for PTSD symptoms. …”
    Get full text
    Article
  9. 29
  10. 30

    Efficacy and safety of telitacicept in IgA nephropathy: a real-world study by Lingqiu Dong, Dandan Yang, Aiya Qin, Siqing Wang, Yi Tang, Jiaxing Tan, Wei Qin

    Published 2025-12-01
    “…Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.Aim To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.Methods Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. …”
    Get full text
    Article
  11. 31
  12. 32
  13. 33

    Context-dependent memory in the real world: the role of frequency and context dwell time by Yura Choi, Kawon Kim, Sunwoo Moon, Geunseong Jung, Jae-Hyuk Cha, Hyungwook Yim

    Published 2025-01-01
    “…Results demonstrated the existence of the context-dependent memory effect in a real-world setting, with low-frequency locations showing a stronger context-dependent memory effect—benefiting more from the matched context. …”
    Get full text
    Article
  14. 34
  15. 35

    Real‐world efficacy of transfusion with liberal or restrictive strategy in traumatic brain injury by Liang‐Wen Cui, Nian Liu, Chao Yu, Ming Fang, Rui Huang, Cheng Zhang, Min Shao

    Published 2025-01-01
    “…Interpretation Compared with the restrictive strategy, the liberal strategy does not improve the short‐term neurological prognosis and death among patients with TBI in a real‐world situation. The liberal strategy may be beneficial to survival at very early stage or in hemodynamically unstable subgroup.…”
    Get full text
    Article
  16. 36
  17. 37

    Advancing the development of real-world data for healthcare research in China: challenges and opportunities by Jun Zhang, Eric Wu, Jia Zhong, Honghao Fang, Larry Liu, Jipan Xie

    Published 2022-07-01
    “…Various real-world data (RWD) sources have emerged in China with the intention of generating real-world evidence (RWE) that can be used in clinical and regulatory decision-making. …”
    Get full text
    Article
  18. 38

    Adverse events in the nervous system associated with blinatumomab: a real-world study by Wen Gao, Jingwei Yu, Yifei Sun, Zheng Song, Xia Liu, Xue Han, Lanfan Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

    Published 2025-02-01
    “…Abstract Background Nervous system toxicity (NST) is a frequent and serious adverse event (AE) associated with blinatumomab, the first bispecific antibody drug targeting CD19 and CD3. Real-world data are needed to better understand the incidence and characteristics of NST in clinical practice. …”
    Get full text
    Article
  19. 39
  20. 40

    Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis by Hui Chen

    Published 2025-01-01
    “…BackgroundOfatumumab, a fully human monoclonal antibody targeting CD20, is approved for the treatment of relapsing multiple sclerosis. Comprehensive real-world safety data are crucial for informing clinical practice.MethodsThe FDA Adverse Event Reporting System database was utilized to perform a disproportionality analysis, covering reports from Q3 2020 to Q2 2024, in which ofatumumab was identified as the primary suspected drug. …”
    Get full text
    Article